[go: up one dir, main page]

WO2006082597A3 - Modification cristalline de derive de 2-oxazolidone 5-substituee et procede associe - Google Patents

Modification cristalline de derive de 2-oxazolidone 5-substituee et procede associe Download PDF

Info

Publication number
WO2006082597A3
WO2006082597A3 PCT/IN2006/000024 IN2006000024W WO2006082597A3 WO 2006082597 A3 WO2006082597 A3 WO 2006082597A3 IN 2006000024 W IN2006000024 W IN 2006000024W WO 2006082597 A3 WO2006082597 A3 WO 2006082597A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxazoiidone
derivative
substituted
crystal modification
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000024
Other languages
English (en)
Other versions
WO2006082597A2 (fr
Inventor
Mohan Anand Chandavarkar
Rajaram Uday Bapat
Vivek Manohar Khare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FDC Ltd
Original Assignee
FDC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FDC Ltd filed Critical FDC Ltd
Publication of WO2006082597A2 publication Critical patent/WO2006082597A2/fr
Publication of WO2006082597A3 publication Critical patent/WO2006082597A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme I polymorphe cristalline d'un composé de 5-(3,5- diméthylphénoxy-) méthyl)-2-oxazolidinone, caractérisée par un diagramme de diffraction aux rayons X présentant des pics aux valeurs 10,355, 14,285, 18,625, 19,030, 20,810 et 22,475 ± 0,30 degrés d'angle 2 thêta, et un point de fusion compris entre 122,5 °C et 124 °C qui est caractérisé par analyse calorimétrique différentielle. La présente invention concerne également des procédés de préparation de ladite forme, des préparations pharmaceutiques comprenant ledit polymorphe et son utilisation dans le traitement de la dépression de transmissions synaptiques centrales.
PCT/IN2006/000024 2005-01-24 2006-01-24 Modification cristalline de derive de 2-oxazolidone 5-substituee et procede associe Ceased WO2006082597A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN71/MUM/2005 2005-01-24
IN71MU2005 2005-01-24

Publications (2)

Publication Number Publication Date
WO2006082597A2 WO2006082597A2 (fr) 2006-08-10
WO2006082597A3 true WO2006082597A3 (fr) 2006-12-21

Family

ID=36777616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000024 Ceased WO2006082597A2 (fr) 2005-01-24 2006-01-24 Modification cristalline de derive de 2-oxazolidone 5-substituee et procede associe

Country Status (1)

Country Link
WO (1) WO2006082597A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007074477A2 (fr) * 2005-12-29 2007-07-05 Dabur Pharma Limited Polymorphes de métaxalone
US20090163561A1 (en) * 2007-12-21 2009-06-25 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062827A (en) * 1959-06-19 1962-11-06 Robins Co Inc A H 5-(3', 5'-dialkylphenoxymethyl)-2-oxazolidones
US3446814A (en) * 1965-07-24 1969-05-27 Henkel & Cie Gmbh Process for the preparation of substituted oxazolidones
WO2003061552A2 (fr) * 2002-01-14 2003-07-31 Sun Pharmaceutical Industries Limited Procede relatif a l'elaboration de 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone sensiblement pure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062827A (en) * 1959-06-19 1962-11-06 Robins Co Inc A H 5-(3', 5'-dialkylphenoxymethyl)-2-oxazolidones
US3446814A (en) * 1965-07-24 1969-05-27 Henkel & Cie Gmbh Process for the preparation of substituted oxazolidones
WO2003061552A2 (fr) * 2002-01-14 2003-07-31 Sun Pharmaceutical Industries Limited Procede relatif a l'elaboration de 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone sensiblement pure

Also Published As

Publication number Publication date
WO2006082597A2 (fr) 2006-08-10

Similar Documents

Publication Publication Date Title
JP2008518904A5 (fr)
EP2457918A3 (fr) Solvates cristallins et complexes de dérivés de (1S)-1,5-anhydro-1-C-((phényl)méthyl) phényl)-d-glucitol avec acides aminés en tant qu'inhibiteurs SGLT2 pour le traitement des diabètes
WO2009080226A3 (fr) Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
JP2007016035A5 (fr)
WO2009149139A8 (fr) Mimétiques de glucocorticoïdes, leurs procédés de fabrication, des compositions pharmaceutiques et leurs utilisations
WO2009050242A3 (fr) Pipérazino-dihydrothiénopyrimidines substituées par un hétérocycle
WO2009080227A3 (fr) Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
RU2013138733A (ru) Конденсированные производные аминодигидротиазина
JP2006514626A5 (fr)
WO2009068170A3 (fr) Dérivés chiraux de 2-(benzylsulfinyl)-thiazole et de 2-[(1h-pyrazol-4-ylméthyl)sulfinyl]-thiazole, procédés pour leur production et leur utilisation en tant qu'herbicides et régulateurs de croissance des végétaux
WO2005095379B1 (fr) Sels d'addition d'acide methanesulfonique cristallins derives de l'imatinib
WO2010067374A3 (fr) Polymorphes de dasatinib
WO2008115999A8 (fr) Composés biaryle et bihétéroaryle utiles pour le traitement des troubles du fer
WO2004096800A3 (fr) Composes organiques
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
WO2009070314A3 (fr) Forme cristalline de sitagliptine
WO2008010238A3 (fr) Nouveaux composés antidiabétiques
WO2009047802A3 (fr) Nouvelle formulation bioadhésive à libération modifiée d'acide 5-aminosalicylique ou de ses sels et de ses métabolites destinée au traitement du colon
WO2006067103A3 (fr) Procede de preparation d'un derive de 2-pyridylethylcarboxamide
WO2010001257A3 (fr) Nouvelles formes à l’état solide de laquinimod et son sel de sodium
WO2007020213A3 (fr) Derives de thiazolylpiperidines
WO2008011110A3 (fr) Composés hétérocycliques à bi-substitution amino et procédés d'utilisation
WO2010010435A3 (fr) Dérivés oxazole et thiazole fusionnés en tant que modulateurs de trpm8
WO2007041077A3 (fr) Derives d'amides heterocycliques utilises en tant qu'agonistes du recepteur rxr pour le traitement de la dyslipidemie, de l'hypercholesterolemie et du diabete
WO2010070677A3 (fr) Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06728386

Country of ref document: EP

Kind code of ref document: A2